Tweet
J Exp Med. Neutralizing antibodies to HIV-1 induced by immunization
[Source: The Journal of Experimental Medicine, full text: (LINK).]
------
Published February 11, 2013 // <CITE><ABBR>JEM</ABBR> vol. 210 no. 2 209-223 </CITE>
<CITE></CITE>
<CITE></CITE>The Rockefeller University Press, doi: 10.1084/jem.20121827 ? 2013 McCoy and Weiss
Review
Neutralizing antibodies to HIV-1 induced by immunization
Laura E. McCoy 1,2 and Robin A. Weiss 1,2
Author Affiliations: <SUP>1</SUP>Wohl Virion Centre and <SUP>2</SUP>Medical Research Council Centre for Medical Molecular Virology, Division of Infection and Immunity, University College London, London WC1E 6BT, England, UK
CORRESPONDENCE Robin A. Weiss: r.weiss@ucl.ac.uk
Abstract
Most neutralizing antibodies act at the earliest steps of viral infection and block interaction of the virus with cellular receptors to prevent entry into host cells. The inability to induce neutralizing antibodies to HIV has been a major obstacle to HIV vaccine research since the early days of the epidemic. However, in the past three years, the definition of a neutralizing antibody against HIV has been revolutionized by the isolation of extremely broad and potent neutralizing antibodies from HIV-infected individuals. Considerable hurdles remain for inducing neutralizing antibodies to a protective level after immunization. Meanwhile, novel technologies to bypass the induction of antibodies are being explored to provide prophylactic antibody-based interventions. This review addresses the challenge of inducing HIV neutralizing antibodies upon immunization and considers notable recent advances in the field. A greater understanding of the successes and failures for inducing a neutralizing response upon immunization is required to accelerate the development of an effective HIV vaccine.
Submitted: 13 August 2012 - Accepted: 11 December 2012
This article is distributed under the terms of an Attribution?Noncommercial?Share Alike?No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution?Noncommercial?Share Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/).
-<CITE></CITE>
<CITE></CITE>The Rockefeller University Press, doi: 10.1084/jem.20121827 ? 2013 McCoy and Weiss
Review
Neutralizing antibodies to HIV-1 induced by immunization
Laura E. McCoy 1,2 and Robin A. Weiss 1,2
Author Affiliations: <SUP>1</SUP>Wohl Virion Centre and <SUP>2</SUP>Medical Research Council Centre for Medical Molecular Virology, Division of Infection and Immunity, University College London, London WC1E 6BT, England, UK
CORRESPONDENCE Robin A. Weiss: r.weiss@ucl.ac.uk
Abstract
Most neutralizing antibodies act at the earliest steps of viral infection and block interaction of the virus with cellular receptors to prevent entry into host cells. The inability to induce neutralizing antibodies to HIV has been a major obstacle to HIV vaccine research since the early days of the epidemic. However, in the past three years, the definition of a neutralizing antibody against HIV has been revolutionized by the isolation of extremely broad and potent neutralizing antibodies from HIV-infected individuals. Considerable hurdles remain for inducing neutralizing antibodies to a protective level after immunization. Meanwhile, novel technologies to bypass the induction of antibodies are being explored to provide prophylactic antibody-based interventions. This review addresses the challenge of inducing HIV neutralizing antibodies upon immunization and considers notable recent advances in the field. A greater understanding of the successes and failures for inducing a neutralizing response upon immunization is required to accelerate the development of an effective HIV vaccine.
Submitted: 13 August 2012 - Accepted: 11 December 2012
This article is distributed under the terms of an Attribution?Noncommercial?Share Alike?No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution?Noncommercial?Share Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/).
------